Sign up to get updates from us
Dr. Jennifer Bath, an expert in antibody discovery, as well as translational work in infectious disease, explains why leaving a tenured professorship was a price worth paying to become the CEO of ImmunoPrecise Antibodies (IPA). Under her leadership, and with B Cell Select, a proprietary discovery platform at her command, IPA is developing a therapeutic antibody cocktail called, Polytope, that has the potential to not only treat current strains of Covid-19, but also emerging variants. She also answers the critical question: Which is more difficult, antibody discovery, or irregular verb forms in French (hint: French is hard…)
